These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22584257)

  • 1. Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.
    Eskesen AN; Melum E; Moghaddam A; Bjøro K; Verbaan H; Ring-Larsen H; Dalgard O
    Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):890-6. PubMed ID: 22584257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
    Thompson AJ; Santoro R; Piazzolla V; Clark PJ; Naggie S; Tillmann HL; Patel K; Muir AJ; Shianna KV; Mottola L; Petruzzellis D; Romano M; Sogari F; Facciorusso D; Goldstein DB; McHutchison JG; Mangia A
    Hepatology; 2011 Feb; 53(2):389-95. PubMed ID: 21274861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.
    Pineda-Tenor D; García-Álvarez M; Jiménez-Sousa MA; Vázquez-Morón S; Resino S
    J Transl Med; 2015 Oct; 13():320. PubMed ID: 26438033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.
    El Raziky M; Zayed NA; Abdel Baki A; Mansour SA; Shahin RMH
    J Med Virol; 2017 Oct; 89(10):1823-1829. PubMed ID: 28480960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.
    Kurosaki M; Tanaka Y; Tanaka K; Suzuki Y; Hoshioka Y; Tamaki N; Kato T; Yasui Y; Hosokawa T; Ueda K; Tsuchiya K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Matsuura K; Sugauchi F; Enomoto N; Nishida N; Tokunaga K; Mizokami M; Izumi N
    Antivir Ther; 2011; 16(5):685-94. PubMed ID: 21817190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment.
    DʼAvolio A; Ciancio A; Siccardi M; Smedile A; Baietto L; Simiele M; Marucco DA; Cariti G; Calcagno A; de Requena DG; Sciandra M; Cusato J; Troshina G; Bonora S; Rizzetto M; Di Perri G
    Ther Drug Monit; 2012 Apr; 34(2):165-70. PubMed ID: 22406654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.
    Di Marco V; Calvaruso V; Grimaudo S; Ferraro D; Pipitone RM; Di Stefano R; Craxì A
    J Viral Hepat; 2013 Feb; 20(2):113-21. PubMed ID: 23301546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ITPA gene variant may protect against anemia induced during pegylated interferon alfa and ribavirin combination treatment in Ukrainian patients with chronic hepatitis C.
    Kucherenko A; Pampukha V; Bobrova I ; Moroz L; Livshits L
    Tsitol Genet; 2015; 49(2):38-41. PubMed ID: 26030972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response.
    Holmes JA; Roberts SK; Ali RJ; Dore GJ; Sievert W; McCaughan GW; Crawford DH; Cheng WS; Weltman MD; Bonanzinga S; Visvanathan K; Sundararajan V; Desmond PV; Bowden DS; Matthews GV; Thompson AJ;
    Hepatology; 2014 Jun; 59(6):2152-60. PubMed ID: 24449403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.
    Thompson AJ; Fellay J; Patel K; Tillmann HL; Naggie S; Ge D; Urban TJ; Shianna KV; Muir AJ; Fried MW; Afdhal NH; Goldstein DB; McHutchison JG
    Gastroenterology; 2010 Oct; 139(4):1181-9. PubMed ID: 20547162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.
    Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Oct; 59(4):667-74. PubMed ID: 23707372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.
    D'Avolio A; De Nicolò A; Cusato J; Ciancio A; Boglione L; Strona S; Cariti G; Troshina G; Caviglia GP; Smedile A; Rizzetto M; Di Perri G
    Antiviral Res; 2013 Oct; 100(1):114-9. PubMed ID: 23933495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients.
    Liu Z; Wang S; Qi W; Wang X; Sun D; Wang H; Zhang Y; Li Z; Zhu L; Zhao P; Guo H; Zhou C; Wang J
    Medicine (Baltimore); 2017 Jul; 96(29):e7554. PubMed ID: 28723780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy.
    Amjed S; Saleem HGM; Ullah S; Latif S; Shabana ; Jafar J; Waqar AB
    BMC Infect Dis; 2024 Mar; 24(1):301. PubMed ID: 38468199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients.
    Ahmed WH; Furusyo N; Zaky S; Eldin AS; Aboalam H; Ogawa E; Murata M; Hayashi J
    World J Gastroenterol; 2013 Mar; 19(9):1387-95. PubMed ID: 23538996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.
    Kozuka R; Hai H; Teranishi Y; Motoyama H; Kawamura E; Hagihara A; Uchida-Kobayashi S; Morikawa H; Enomoto M; Murakami Y; Kawada N; Tamori A
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1495-1502. PubMed ID: 28109022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
    Tahata Y; Hiramatsu N; Oze T; Urabe A; Morishita N; Yamada R; Yakushijin T; Hosui A; Oshita M; Kaneko A; Hagiwara H; Mita E; Ito T; Yamada Y; Inada M; Katayama K; Tamura S; Imai Y; Hikita H; Sakamori R; Yoshida Y; Tatsumi T; Hayashi N; Takehara T
    J Med Virol; 2016 Oct; 88(10):1776-84. PubMed ID: 26991414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.
    Naggie S; Rallon NI; Benito JM; Morello J; Rodriguez-Novoa S; Clark PJ; Thompson AJ; Shianna KV; Vispo E; McHutchison JG; Goldstein DB; Soriano V
    J Infect Dis; 2012 Feb; 205(3):376-83. PubMed ID: 22158703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin.
    Hai H; Tamori A; Enomoto M; Morikawa H; Uchida-Kobayashi S; Fujii H; Hagihara A; Kawamura E; Thuy le TT; Tanaka Y; Kawada N
    J Gastroenterol Hepatol; 2014 Jan; 29(1):201-7. PubMed ID: 23980585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients.
    Nishimura T; Osaki R; Shioya M; Imaeda H; Aomatsu T; Takeuchi T; Okumura Y; Fujiyama Y; Andoh A
    Mol Med Rep; 2012 Feb; 5(2):517-20. PubMed ID: 22052220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.